



**Good turnover performance confirmed
with growth of 13.07% in H1 2016**

In €M	2016	2015	Change
Q1	30.46	27.04	+ 12.65%
Q2	33.07	29.15	+ 13.45%
Total H1	63.53	56.19	+ 13.07%

Group consolidated turnover as at 30 June 2016 totalled €63.53 million, up 13.07% compared with 30 June 2015.

The Group continues with the construction of its technological platform and its range of patient care services: the performances from the Solutions for sanitary and medico-social establishments and Solutions for e-Health Divisions confirm the coherence of the PHARMAGEST Group's diversification strategy.

Business update:

- **The Solutions for Pharmacy Division - Europe** achieved a turnover of €49.57 million as at 30 June 2016, down slightly by 1% (€50.07 million) compared with 30 June 2015, with a negative cycle effect on rental contracts in the first half. However, recurring turnover recorded 2.7% growth. This Division accounted for 78% of the Group's overall turnover, versus 89% in H1 2015.
- **The Solutions for sanitary and medico-social establishments Division** generated a turnover of €4.99 million for first-half 2016, showing strong growth of 52.96% in comparison with first-half 2015. As a reminder, MALTA INFORMATIQUE acquired the company DICSIT INFORMATIQUE at the end of March. The turnover from this new acquisition has been integrated from 1 April 2016. This Division accounted for 7.85% of the PHARMAGEST Group's overall turnover (versus 5.80% in H1 2015).
- **The Solutions for e-Health Division** also posted a very good performance with a turnover of €4.71 million as at 30 June 2016, up 66.84% on 30 June 2015. The Solutions for e-Health Division accounted for 7.42% of total PHARMAGEST Group turnover in H1 2015 (as against 5.03% in first-half 2015).
- **The Fintech Division**, created only a year ago, achieved a turnover of €4.25 million in the first half of 2016. After an encouraging first quarter (turnover of €1.68 million), the second quarter confirmed the excellent performance of the Fintech Division (turnover of €2.58 million) and accounted for 6.70% of the Group's overall turnover for first-half 2016.

Outlook:

The PHARMAGEST Group's innovation strategy in the field of patient care is constantly increasing the level of interaction between its Divisions:

- The teams from the Solutions for Pharmacy Division - Europe, while continuing the development and roll-out of innovative solutions, are also working together with teams from the Solutions for e-Health Division to offer solutions with higher added value that drive the growth and sustainability of the PHARMAGEST Group.
- The Solutions for e-Health Division confirms the relevance of its investments in researching technological solutions for allowing individuals who have lost some independence to remain at home, and the knowledge of the Solutions for sanitary and medico-social establishments Division completes these devices, effectively meeting the needs of care homes, hospitals at home and home-based nursing services when it comes to patient care.
- Created in Q2 2015, the Fintech Division has rapidly confirmed its performances on the market. This new Division aims to quickly offer the use of its marketplace for the funding of goods and services beyond the French market whilst developing international partnerships.

PHARMAGEST INTERACTIVE financial calendar reminder:

- Publication of half-year results on 12 September 2016.
- Publication of Q3 2016 turnover on 16 November 2016.

About the PHARMAGEST Group:

The PHARMAGEST Group is the French leader in pharmacy information technology, with a 43.5% share of the market and over 800 employees. The strategy of the PHARMAGEST Group is based on a core business – innovating in information technology to improve healthcare – and on the development of two priority focuses: services and technologies for healthcare professionals, notably support for pharmacists in monitoring patient compliance; and technology for improving the efficacy of healthcare systems.

To roll out that strategy, the PHARMAGEST Group has developed specialised businesses, including pharmacy IT, e-Health solutions, solutions for healthcare professionals, solutions for laboratories, connected health devices and apps, and a sales financing marketplace. These businesses are divided into 4 Divisions: the Solutions for Pharmacy Division – Europe, the Solutions for Sanitary and Medico-Social Establishments Division, the Solutions for e-Health Division, and the FinTech Division.

Listed on Euronext Paris™ - Compartment B
 Indices: ENTERNEXT TECH 40, CAC @ SMALL and CAC @ All-Tradable by inclusion
 Eligible for the Long-Only Deferred Settlement Service (SRD)
 ISIN: FR0012882389 – Reuters: PHA.PA – Bloomberg: PMGI FP
PHARMAGEST shares are eligible for France's Equity Savings Plan intended to finance SMEs (PEA-PME)



For all the latest news, go to www.pharmagest.com

CONTACTS

Analyst and Investor Relations:

Chief Financial Officer: Jean-Yves SAMSON
 Tel. +33 (0)3 83 15 90 67 – jean-yves.samson@pharmagest.com

Press Relations:

FIN'EXTENSO – Isabelle APRILE
 Tel. +33 (0)1 39 97 61 22 - i.aprile@finextenso.fr